Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is X-linked hereditary disease from the group of lysosomal storage disease. Its prevalence is 3-7 cases per 1 million live-born boys. MPS II occurs due to the deficiency of iduronate-2-sulfatase enzyme because of pathological changes in the str...
Saved in:
Main Authors: | Nato D. Vashakmadze (Author), Natalya V. Zhurkova (Author), Olga B. Gordeeva (Author), Elena V. Komarova (Author), Tatyana E. Privalova (Author), Anastasya I. Rykunova (Author), Marina А. Babaykina (Author) |
---|---|
Format: | Book |
Published: |
"Paediatrician" Publishers LLC,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Idursulfase Beta (Hunterase) Therapeutic Experience in a Patient with Mucopolysaccharidosis Type II
by: Nato D. Vashakmadze, et al.
Published: (2023) -
Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency
by: Nato D. Vashakmadze, et al.
Published: (2020) -
Intracerebroventricular Enzyme Replacement Therapy in Patients with Neuropathic Form of Mucopolysaccharidosis Type II: to Help Practicing Physician
by: Nataliya V. Zhurkova, et al.
Published: (2024) -
Results of 14-year-long Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II: Clinical Case
by: Natalia V. Zhurkova, et al.
Published: (2023) -
Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2021)